A veterinary tranquilizer called xylazine is infiltrating street drugs, deepening addiction, baffling law enforcement and causing wounds so severe that some result in amputation. View original article Contributor: Jan Hoffman
The drug, Leqembi, may modestly slow cognitive decline in early stages of the disease but carries some safety risks. Still, data suggests it is more promising than the small number of other available treatments. View original article Contributor: Pam Belluck
You do not have to spend a lot of money to get glowing, flawless-looking skin and keep it all year long. Using the right skincare regimen and following these New … Click to Continue » View original article Contributor:
Living in a bilingual city like Miami I’m used to hearing a mash-up of languages. And I appreciate learning how other languages have food-related words that make me say, “That … Click to Continue » View original article Contributor:
A veterinary tranquilizer called xylazine is infiltrating street drugs, deepening addiction, baffling law enforcement and causing wounds so severe that some result in amputation. View original article Contributor: Jan Hoffman
On Jan. 6, the U.S. Food and Drug Administration (FDA) approved a new drug to treat Alzheimer’s disease in its early stages. Lecanemab, which will be available under the name Leqembi, can slow the cognitive decline associated with Alzheimer’s disease by 27%, according to data submitted to the FDA by the drug’s developers, Eisai and … Read more
Somewhere along the long, winding road of evolution, a bunch of genes got together in a conference room and decided it would probably be most optimal for human survival if we were forced to take in every sound all around us at all times. Thus, the ear was born. Unlike their neighbors the eyes, the … Read more
There are few conditions as exhausting—and common—as burnout. According to a 2022 Gallup poll, 76% of American workers report experiencing the end-of-their-rope fatigue and frustration that are the hallmarks of the condition at least some of the time. Burnout cuts across age, gender, and socioeconomic lines, and has only grown worse over the past three … Read more
The drug, lecanemab, removes a sticky protein from the brain called amyloid beta, which is thought to play a key role in the memory-robbing illness. View original article Contributor: Laurie McGinley
The drug, Leqembi, may modestly slow cognitive decline in early stages of the disease but carries some safety risks. Still, data suggests it is more promising than the small number of other available treatments. View original article Contributor: Pam Belluck